Stocks Health care BEAM
NASDAQ · Health careBeam Therapeutics Inc. (BEAM)
Beam Therapeutics Inc. brought in $146.6M of revenue over the twelve months to September 30, 2026, up 163.3% from a year earlier. It posted a net loss of $108.4M. In fiscal 2025 capital spending exceeded operating cash flow by $360M. At September 30, 2026 it held $213.3M in cash against $100.4M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Beam Therapeutics Inc.
- Net worth
- Beam Therapeutics Inc. has a market value (market cap) of $2.6B at the latest share price, and shareholders' equity of $952.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $139.7M (+120.0% year on year), with a net loss of $80M. Over the 12 months to September 30, 2026: revenue $146.6M, net loss $108.4M.
- Cash flow
- In fiscal 2025 operations used $345.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Beam Therapeutics Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Beam Therapeutics Inc. does
Beam Therapeutics Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker BEAM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $139.7M | -$80M | -$0.81 | -$360M |
| 2024 | $63.5M | -$376.7M | -$4.58 | -$356.2M |
| 2023 | $377.7M | -$132.5M | -$1.72 | -$182.9M |
| 2022 | $60.9M | -$289.1M | -$4.13 | -$26.4M |
| 2021 | $51.8M | -$370.6M | -$5.77 | -$113.1M |
| 2020 | $24K | -$194.6M | -$4.19 | -$112.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where BEAM ranks in Health care
Latest SEC filings
What Beam Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 97% to $307K versus the same quarter last year; diluted EPS -$1.28 versus -$1.10.
- November 3, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 94% to $490K versus the same quarter last year; diluted EPS -$1.18 versus -$1.00.
- August 4, 2026
- June 8, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 325% to $31.7M versus the same quarter last year; diluted EPS -$0.91 versus -$1.23.
- May 7, 2026
- April 29, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Beam Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.2M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 16, 2026 | Evans John M.CEO, Director | Exercised options | 25,000 | $25.8K |
| October 16, 2026 | Evans John M.CEO, Director | Soldpre-planned (10b5-1) | 25,000 | $599.6K |
| October 15, 2026 | Evans John M.CEO, Director | Exercised options | 25,000 | $25.8K |
| October 15, 2026 | Evans John M.CEO, Director | Soldpre-planned (10b5-1) | 25,000 | $589.2K |
| October 1, 2026 | Cavanagh Bethany JSVP, Finance and Treasurer | Soldpre-planned (10b5-1) | 187 | $4.6K |
| September 24, 2026 | Ciaramella GiuseppePresident | Gave as a gift | 123,407 | - |
| July 27, 2026 | Simon AmyChief Medical Officer | Soldpre-planned (10b5-1) | 16,667 | $429K |
| June 30, 2026 | Simon AmyChief Medical Officer | Soldpre-planned (10b5-1) | 373 | $13K |
Who owns BEAM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 12.6% | February 5, 2026 |
| Dapice Joshua J.13G, passive with 30 related filers | 9.99% | February 5, 2026 |
| Farallon Capital Management, L.L.C.13G, passive with 28 related filers | 9.99% | August 13, 2026 |
| ARK Investment Management LLC13G, passive with 1 related filers | 9.95% | August 14, 2026 |
| Vanguard Capital Management13G, passive | 5.02% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 277 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 12,609,002 | +156,803 |
| Farallon Capital Management, L.L.C. | 10,236,396 | +101,700 |
| ARK Investment Management LLC | 10,234,862 | -1,898,571 |
| BlackRock, Inc. | 8,997,542 | +509,973 |
| State Street Corp | 5,827,122 | +127,857 |
| Vanguard Portfolio Management LLC | 4,921,259 | +350,462 |
| Vanguard Capital Management LLC | 4,599,437 | +222,063 |
| ARCH Venture Management, LLC | 4,540,132 | 0 |
| Sumitomo Mitsui Trust Group, Inc. | 3,455,043 | -370,542 |
| Amova Asset Management Americas, Inc. | 3,455,043 | -370,542 |
| Kynam Capital Management, LP | 2,840,792 | -841,393 |
| Geode Capital Management, LLC | 2,596,963 | +178,371 |
| Dimensional Fund Advisors LP | 2,225,844 | +71,269 |
| Morgan Stanley | 1,950,969 | +1,302,705 |
| Contrarius Group Holdings Ltd | 1,614,538 | +1,081,095 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,551,781 | -101,933 |
| Two Sigma Investments, LP | 1,388,227 | +177,374 |
| Casdin Capital, LLC | 1,350,000 | 0 |
| Goldman Sachs Group Inc | 1,310,059 | +304,316 |
| Redmile Group, LLC | 1,164,259 | -73,400 |
Insiders
7 insiders reported holding 2,384,139 shares in total, about $60M at the last price.
| Holder | Shares |
|---|---|
| Evans John M.CEO, Director | 1,047,205 |
| Fmr LLC10% owner | 854,583854,583 held indirectly |
| Ciaramella GiuseppePresident | 130,504 |
| Bellon ChristineChief Legal Officer | 109,711 |
| Emany Sravan KumarChief Financial Officer | 105,456 |
| Simon AmyChief Medical Officer | 85,696 |
| Cavanagh Bethany JSVP, Finance and Treasurer | 50,984 |
Questions about BEAM
What does Beam Therapeutics Inc. do?
Beam Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as BEAM. Its shares trade on NASDAQ under the ticker BEAM.
What is Beam Therapeutics Inc.'s net worth?
Beam Therapeutics Inc. has a market value (market cap) of $2.6B at the latest share price, and shareholders' equity of $952.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Beam Therapeutics Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $108.4M on revenue of $146.6M.
How much revenue does Beam Therapeutics Inc. make?
Over the twelve months to September 30, 2026 Beam Therapeutics Inc. reported revenue of $146.6M. That is 163.3% more than a year earlier.
When did Beam Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026.
When is Beam Therapeutics Inc.'s next earnings report?
Beam Therapeutics Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BEAM with
Follow BEAM
Get an email when Beam Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Beam Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.